Specifically, miR-17 and miR-20a have been shown to be upregulated by 1.7–3.36 fold in estradiol-treated ER+ breast cancer cell lines via ERα-induced MYC/c-MYC upregulation [32, 39, 57, 58]. Here, MYC is linked to breast carcinoma.